RXi Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare
MARLBOROUGH, Mass., May 27, 2014
MARLBOROUGH, Mass., May 27, 2014 /PRNewswire/ --RXi Pharmaceuticals
Corporation (NASDAQ: RXII), a biotechnology company focused on discovering,
developing and commercializing innovative therapies addressing major unmet
medical needs using RNA-targeted technologies, todayannounced that the
Company's President & CEO, Dr. Geert Cauwenbergh, will present at the
Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014 at 8:00
a.m. EDT. Dr. Cauwenbergh will discuss the development of RXI-109, a
self-delivering RNAi compound designed to reduce dermal scarring, as well as
business development opportunities with RXi's sd-rxRNA® technology platform.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
The presentation will be webcast and available on the "Investors" section of
the Company's website, www.rxipharma.com.
About Jefferies 2014 Global Healthcare Conference
This conference will feature an extensive range of public and private
healthcare companies across the biopharmaceuticals, life sciences, healthcare
services, healthcare IT and medical technology sectors, with over 300
participating companies and 2,500 attendees. This global gathering of leading
executives, institutional investors, private equity investors and VCs will
address near- and long-term investment opportunities and discuss the
mechanisms driving healthcare in the U.S. and internationally. This conference
will take place June 2-5, 2014 in New York City.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company
focused on discovering, developing and commercializing innovative therapies
based on its proprietary, self-delivering RNAi platform. Therapeutics that use
RNA interference, or "RNAi," have great promise because of their ability to
down-regulate the expression of specific genes that may be over-expressed in
disease conditions. Building on the pioneering work of scientific founder and
Nobel Laureate Dr. Craig Mello, a member of the Company's Scientific Advisory
Board, RXi's first RNAi product candidate, RXI‑109, entered into human
clinical trials in June 2012 and is currently in Phase 2. RXI-109 targets
connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis).
For more information, please visit www.rxipharma.com.
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about future expectations, planned and
future development of RXi Pharmaceuticals Corporation's products and
technologies. Forward-looking statements about expectations and development
plans of RXi's products involve significant risks and uncertainties: the risk
that we may not be able to successfully develop our candidates, or that
development of RNAi-based therapeutics may be delayed or not proceed as
planned, or that we may not develop any RNAi-based products; risks that the
development process for our product candidates may be delayed, risks related
to the development and commercialization of products by our competitors, the
risk related to our ability to control the timing and terms of collaborations
with third parties, and the possibility that other companies or organizations
may assert patent rights preventing us from developing our products. Actual
results may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur after the
date of this release.
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
SOURCE RXi Pharmaceuticals Corporation
Press spacebar to pause and continue. Press esc to stop.